Vyleesi Disease Interactions

Bremelanotide is contraindicated in patients who have uncontrolled hypertension or known cardiovascular disease, as it transiently increases blood pressure and reduces heart rate after each dose. Before initiating bremelanotide, and periodically during treatment, consider the patient's cardiovascular risk and ensure blood pressure is well-controlled.

Bremelanotide has not been evaluated in patients with severe hepatic impairment and should be used with caution in these patients (Child-Pugh C; score 10-15), because they may have an increase in the incidence and severity of adverse reactions (e.g., nausea and vomiting). No dosing adjustments are recommended for patients with mild to moderate (Child-Pugh A and B; score 5-9) hepatic impairment.

Use bremelanotide with caution in patients with severe (eGFR <30 mL/min/1.73 m2) renal impairment, because these patients may have an increase in the incidence and severity of adverse reactions (e.g., nausea and vomiting). No dosing adjustments are recommended for patients with mild to moderate (eGFR 30-89 mL/min/1.73 m2) renal impairment.